Evercore ISI maintains Outperform on Insmed, cuts target to $160
Evercore ISI Group analyst Josh Schimmer maintained an Outperform rating on Insmed (NASDAQ: INSM) while lowering the price target to $160 from $162.

*this image is generated using AI for illustrative purposes only.
Evercore ISI Group analyst Josh Schimmer has maintained an Outperform rating on Insmed (NASDAQ: INSM). The firm adjusted its valuation by lowering the price target to $160 from $162.
The rating update reflects a revised outlook on the stock's potential while retaining a positive stance on its performance. The new price target represents a slight decrease from the previous estimate of $162.
What factors contributed to the slight reduction in Insmed's price target?
How might Insmed's upcoming clinical trials impact its stock performance?
What are the potential market reactions to future earnings reports?

























